MedTrace Logo

Ex VIvo DEtermiNed Cancer Therapy

NCT05231655 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-02-24

No results posted yet for this study

Summary

EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments. Patients undergoing standard care surgery to excise their tumour, those undergoing a biopsy, or those having a fluid aspirate of a solid tumour with surplus tissue available after diagnostic use will be eligible for this study. The specimen will then be assessed with ex vivo drug screening utilising all standard therapies and therapies that are more novel and in early stages of development. The results of the ex vivo drug screen will be compared to the cancer's actual response to standard care treatments for those that undergo therapy to determine how effective the test is at predicting treatment response.

Conditions

Interventions

DIAGNOSTIC_TEST

Functional drug screen

High-throughput ex-vivo drug screen of cells processed directly from solid tumours to determine sensitivity / resistance profiles

Sponsors & Collaborators

  • University of Sheffield

    collaborator OTHER

  • Sheffield Teaching Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Sarah Danson, PhD, FRCP · University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-07
Primary Completion
2026-01-31
Completion
2027-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05231655 on ClinicalTrials.gov